Stock 600267 ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Zhejiang Hisun Pharmaceutical Co., Ltd.

Equities

600267

CNE0000013Z2

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-27 EDT 		5-day change 1st Jan Change
7.8 CNY -1.76% Intraday chart for Zhejiang Hisun Pharmaceutical Co., Ltd. -4.06% -16.67%
05-20 Hisun Pharma's Veterinary Arm Gets Approval to Register Amoxicillin and Clavulanate Potassium Dry Suspension MT
05-16 Hisun Pharma's Veterinary Arm Gets Nod to Market Selamectin Drops MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The company's share price in relation to its net book value makes it look relatively cheap.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. Stock Zhejiang Hisun Pharmaceutical Co., Ltd.
-16.67% 1.27B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.59% 727B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.89% 347B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.66% 319B
B-
ABBVIE INC. Stock AbbVie Inc.
+0.24% 274B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.38% 238B
B+
NOVARTIS AG Stock Novartis AG
+7.09% 204B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-6.38% 203B
A+
AMGEN INC. Stock Amgen Inc.
+4.23% 161B
C+
PFIZER, INC. Stock Pfizer, Inc.
-1.70% 160B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 600267 Stock
  4. Ratings Zhejiang Hisun Pharmaceutical Co., Ltd.